Resources

In today’s biopharma landscape, resilience isn’t enough — CDMOs must also be agile. Agility enables clients to adjust quickly to clinical changes, market dynamics, or global disruptions without derailing timelines or budgets. In this article, BioCina’s Chief Commercial Officer Jason Arcediano, Vice President and General Manager, Adelaide Michael Tsaconas, and President of Australia Operations Brett […]

The pandemic proved that mRNA-based vaccines could be developed, manufactured, and distributed globally in record time. But the real promise of mRNA is only beginning to unfold. Developers are now targeting mRNA applications across therapeutic areas from rare disease and oncology to gene and cell therapy. In this article, BioCina experts explore the post-pandemic future

Lipid nanoparticles (LNPs) have transformed how we deliver mRNA. But their role in modern medicine is just beginning. In this new expert-authored article, BioCina explores how LNPs are being engineered to deliver a wider range of payloads, including siRNA, gene-editing systems, peptides, and small molecules, across therapeutic areas from oncology to neurology. In this article,

Thousands of mRNA-based vaccines and therapies are in development, but progressing from discovery to clinical trials is far from simple. Developers need more than just capacity; they require a partner who can integrate complex workflows, ensure quality, and speed up timelines. In BioCina’s latest article, Vice President of Business Development and Commercial Operations, Dr. Jan

Speed, complexity, and quality—it’s no longer enough to pick two. In BioCina’s latest article, senior leaders share how the company’s unified CDMO platform eliminates traditional handoffs, enabling biotech innovators to scale smarter and reach patients faster. With operations spanning from pDNA and mRNA to blow–fill–seal and aseptic vial/syringe fill, BioCina brings true integration to biomanufacturing.

Biopharmaceutical companies are under mounting pressure to move faster, spend less, and ensure global compliance all without compromising innovation. This is especially true in clinical-stage manufacturing, where timelines and capital efficiency are everything. In this new expert-authored article, BioCina explores why Australia is emerging as a global hub for biomanufacturing and how sponsors can benefit